CTAS vs TNGX · P/E 51, rev $11.26B vs $5.36B cap
Cintas Corporation (CTAS) versus Tango Therapeutics Inc (TNGX) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Tango Therapeutics Inc (TNGX) is a biotechnology company listed on NASDAQ.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported TNGX revenue for 2026-06-30 was $0. Net income was -$100.9M. TNGX currently screens at market cap $5.36B.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. TNGX currently screens at market cap $5.36B.
Not investment advice. Open the CTAS and TNGX stock pages for the full models.
Not investment advice.